New phosphatidylinositol 3-kinase inhibitors for cancer (Q37851994)

24 August 2017

1 reference

title

New phosphatidylinositol 3-kinase inhibitors for cancer (English)

1 reference

24 August 2017

Daniel W Bowles

1

1 reference

24 August 2017

Antonio Jimeno

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

507-518

1 reference

Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The activation of Akt/PKB signaling pathway and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The PKB/AKT pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Akt inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PIK3CA as an oncogene in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PIK3CA alterations in primary (de novo) and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Chemotherapy maintenance: an option for prolonged survival in malignant peritoneal mesothelioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

A new mutational AKTivation in the PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PTEN-deficient cancers depend on PIK3CB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Will the real Cowden syndrome please stand up: revised diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Understanding the cancer stem cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Chemically targeting the PI3K family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

Patterns ofPIK3CA alterations in familial colorectal and endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562192

10.1517/13543784.2011.562192

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference